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Abstract
Background: The rate of women with substance abuse issues is increasing. Women present with a unique
constellation of risk factors and presenting needs, which may include specific needs in their role as mothers.
Numerous integrated programs (those with substance use treatment and pregnancy, parenting, or child services)
have been developed to specifically meet the needs of pregnant and parenting women with substance abuse
issues. This synthesis and meta-analysis reviews research in this important and growing area of treatment.
Methods: We searched PsycINFO, MedLine, PubMed, Web of Science, EMBASE, Proquest Dissertations, Sociological
Abstracts, and CINAHL and compiled a database of 21 studies (2 randomized trials, 9 quasi-experimental studies, 10
cohort studies) of integrated programs published between 1990 and 2007 with outcome data on maternal
substance use. Data were summarized and where possible, meta-analyses were performed, using standardized
mean differences (d) effect size estimates.
Results: In the two studies comparing integrated programs to no treatment, effect sizes for urine toxicology and
percent using substances significantly favored integrated programs and ranged from 0.18 to 1.41. Studies
examining changes in maternal substance use from beginning to end of treatment were statistically significant and
medium sized. More specifically, in the five studies measuring severity of drug and alcohol use, the average effect
sizes were 0.64 and 0.40, respectively. In the four cohort studies of days of use, the average effect size was 0.52. Of
studies comparing integrated to non-integrated programs, four studies assessed urine toxicology and two assessed
self-reported abstinence. Overall effect sizes for each measure were not statistically significant (d = -0.09 and 0.22,
respectively).
Conclusions: Findings suggest that integrated programs are effective in reducing maternal substance use.
However, integrated programs were not significantly more effective than non-integrated programs. Policy
implications are discussed with specific attention to the need for funding of high quality randomized control trials
and improved reporting practices.
Background
Rates of substance abuse in women are on the rise [1-4].
Research suggests that women are more vulnerable to
the adverse physiological consequences associated with
substance abuse [5]. Substance abuse in women is also
associated with a unique constellation of risk factors
and needs, including increased prevalence of mental
health problems, histories of physical or sexual abuse
[6,7], serious medical problems, poor nutrition, relation-
ship problems (including domestic violence), and deficits
in social support [8,9]. These unique risk factors and
presenting needs of women have resulted in the devel-
opment of numerous women-specific comprehensive
treatment models that address the full range of needs
and include components such as trauma-specific and
trauma informed therapy [4].
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on the unique needs of women, there is also a need to
understand women who abuse substances in their role
as mothers. The majority of women who abuse sub-
stances are of child- bearing age [10]. As such, sub-
stance abuse also has implications for child health and
parenting. Children born to women who used sub-
stances during pregnancy are at greater risk for prema-
turity, low birth weight, impaired physical growth and
development, behavioral problems, learning disabilities,
and substance use [2,11]. Women who continue to
abuse substances after childbirth, despite their best
intentions are at risk for a wide range of parenting defi-
cits [12].
Given the specific risks and needs of women with sub-
stance abuse issues and their children, researchers, clini-
cians, and policy makers have recommended that
substance use treatment programs address women’s
physical, social, and mental health needs, as well as chil-
dren’s needs through prenatal services, parenting pro-
grams, child care, and other child-centered services
[13-15]. This recognition has resulted in the develop-
ment of numerous integrated (or comprehensive) treat-
ment programs (those that include on-site pregnancy-,
parenting-, or child-related services with addiction ser-
vices) in countries, such as the United States and
Canada.
A theoretical rationale for including pregnancy-, par-
enting-, or child-related services with substance use ser-
vices is that integrated treatment programs may
enhance the impact of substance use treatment because
a) integrated programs may reduce barriers to engaging
and remaining in treatment (such as lack of adequate
child care [16]), b) integrated interventions may have a
synergistic effect (e.g., mental health services for mother
may improve mood which may be associated with
reduced substance use), and c) parenting and child
development services may increase maternal motivation
to reduce substance use. Certainly in their development
and evaluation of integrated programs, The Centre for
Substance Abuse Treatment [17] has suggested that
“treatment that addresses the full range of a woman’s
needs is associated with increased abstinence and
improvement in other measures of recovery, including
parenting skills and overall emotional health. Treatment
that addresses alcohol and other drug abuse only may
well fail and contribute to a higher potential for relapse.”
As the number of integrated programs has grown over
the past 20 years, empirical evidence about the effective-
ness of these programs has accumulated. Although
some individual studies examining the effectiveness of
integrated treatment programs suggest positive out-
comes, the study quality varies, ranging from rando-
mized controlled trials to less rigorous single-group
designs. As such, questions remain regarding the robust-
ness of treatment effects relative to non-integrated sub-
stance use programs. Many studies have been limited by
inadequate statistical power (small sample size), compli-
cating interpretation of results.
A few systematic reviews and a meta-analysis examin-
ing outcomes associated with gender specific (women-
only) treatment programs have been completed. In a
systematic review of 38 studies on substance abuse
treatment for women, Ashley et al. [2] examined six spe-
cific components of treatment programs. Programs with
prenatal care, child care, and parenting were associated
with higher rates of abstinence and reduced substance
use. Orwin, Francisco, and Bernichol [18] conducted a
meta-analysis of studies on the effects of substance
abuse treatment for women on substance use, maternal
well-being, and pregnancy outcomes. Findings suggested
that enhancing women-only treatment programs with
prenatal care or therapeutic child care added value
above and beyond the effects of standard women-only
programs. However, neither of these studies specifically
focused on integrated programs and they did not
include the recent proliferation of studies of integrated
programs.
Synthesizing current research on women-specific pro-
grams that include child and/or parenting components
(i.e., integrated programs) is a pressing task given that
1) increased funding is being directed towards support-
ing integrated treatment programs, 2) a proliferation of
programs have been developed, and 3) an increased
number of evaluations have been conducted. Before
more resources are spent on these programs and
research, existing literature needs to be synthesized to
e n h a n c eo u rk n o w l e d g ea n dd e l i n e a t ep r i o r i t i e sa n d
directions for future research (cf. Cooper & Hedges
[19]). While a synthesis does not provide a conclusive
statement about a problem or treatment area, it can
provide pivotal information for the field on what can be
improved. Precise and reliable research syntheses will
assist in ensuring that the next wave of primary research
is sent off in the most illuminating direction [19].
Meta-analysis is well suited to the task of research
synthesis and to addressing the limitations in the cur-
rent literature. First, meta-analysis addresses the pro-
blem of low statistical power by allowing the results of
small-sample studies to be combined, resulting in
increased statistical power. Dennis, Huebner, and
McLellan [20] found that 87% of the studies in Edwards
and Steinglass’s[ 2 1 ]m e t a - a n a l y s i so fa l c o h o l i s mi n t e r -
ventions did not meet the minimum level of acceptable
power, thus placing them at high risk for missing exist-
ing treatment effects.
Similarly, in our evaluation of New Choices, an inte-
grated outpatient program, many results were
Milligan et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:21
http://www.substanceabusepolicy.com/content/5/1/21
Page 2 of 14moderate in strength but failed to reach statistical sig-
nificance [22]. Thus, meta-analysis can increase inter-
pretability of findings and allow more reliable
conclusions about treatment effectiveness. Second, the
strength of the intervention effect can be determined
by meta-analysis through the use of effect size statis-
tics. The strength of observed effects is less influenced
by statistical power than tests of significance and is
more clinically relevant [23]. Third, the generalizability
of findings from a meta-analysis is greater than that of
findings from individual studies because meta-analytic
findings are based on a diverse set of study samples
rather than a single study sample [24]. Fourth, unlike
qualitative reviews, meta-analysis allows one to statisti-
cally determine if the strength of the treatment effects
differs significantly among studies and then to quanti-
tatively examine what factors, such as program, client,
and study characteristics, may be responsible for these
differences. For example, variations in study quality
can be examined statistically for their potential impact
on study findings.
Meta-analysis is an appropriate way to combine results
even in circumstances where there are few studies and,
in fact, the situation is not uncommon. A common mis-
conception is that meta-analysis is applicable only to
research areas involving large numbers of studies. How-
ever, meta-analysis can be applied effectively to a small
number of studies on a focused topic [25]. Some have
argued that focused meta-analyses are more relevant to
informing policy [26] and several meta-analyses in the
field of substance abuse treatment reflect this approach
[25]. According to Cooper and Hedges [19],
If the research question is important, it would be
interesting to know how much research there is on the
problem, even if the answer was none at all... Ultimately
the arbiter of whether a synthesis is needed will not be
numerical standards, but the fresh insights a synthesis
can bring to a field. Indeed, although a meta-analysis
cannot be performed without data, many social scien-
tists see value in empty syntheses that point to impor-
tant gaps in our knowledge.
In this paper, we examine the impact of integrated
treatment programs on maternal substance use. We
hypothesize that participation in integrated programs is
associated with significant improvements in maternal
substance use outcomes and that maternal substance
use outcomes are significantly better for women partici-
pating in integrated programs than women participating
in non-integrated programs. We examine the strength
of these effects and, if there is variability in effects
among studies, we examine client, program, and study
characteristics that may moderate the impact of
treatment.
Method
Literature search
We used three main strategies to identify outcome stu-
dies of intervention programs for women with substance
use issues and their children: online bibliographic data-
base searches; checking printed sources; and requests to
researchers (cf., Mullen [27]; Rosenthal [23]). First, we
searched relevant bibliographic databases (PsycINFO,
MedLine, PubMed, Web of Science, EMBASE, Proquest
Dissertations, Sociological Abstracts, and CINAHL) for
studies published in English, using the terms “substance
use/abuse,”“ addiction,”“ alcoholism,”“ intervention,”
“treatment,”, “therapeutic,”“ rehabilitation,”“ women,”
“child,”“ mother,”“ infant,”“ mental health,”“ parenting,”
and “prenatal” (singly and in combination).
Secondly, we examined reference lists of retrieved arti-
cles for potentially relevant documents. In addition, we
manually searched relevant journals in the area (Journal
of Substance Abuse Treatment, Journal of Substance
Use, Substance Use and Misuse, Journal of Psychoactive
Drugs, Addiction, Journal of Drug Issues, The Interna-
tional Journal of the Addictions, Addictive Behaviors,
and the Journal of Substance Abuse). Documents that
appeared to be relevant on the basis of titles or abstracts
were retrieved.
Finally, we searched for grey data (technical reports,
unpublished data) to ensure our review was not biased
to published sources. All researchers identified through
all search strategies described, as well as researchers
presenting at relevant conferences identified using Goo-
gle and Cross Currents (Upcoming Events), were con-
tacted by email to request any relevant published or
unpublished data. Of the 200 researchers identified and
emailed, 48% responded and 28 additional studies were
identified. In total, 327 studies were retrieved and coded
for eligibility.
Eligibility criteria and study inclusion
Figure 1 depicts the process and outcomes of eligibility
coding. Studies were included in our larger meta-analy-
sis project if:
1) study participants were women who were pregnant
or parenting;
2) all study participants had substance use problems at
baseline;
3) the treatment program included at least one sub-
stance use treatment and at least one child (< 16 years)
treatment service (e.g., prenatal care, child care, parent-
ing classes);
4) the program was not for men or for women not
pregnant or parenting;
5) the program was not a smoking cessation program;
and
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treatment completion, maternal substance use, maternal
well-being, or child well-being.
Using these criteria, 120 studies were considered eligi-
ble for inclusion in the meta-analysis. Based on a ran-
dom sample of 20% of the studies, inter-rater reliability
for eligibility coding was high, Kappa = 0.81. Discrepan-
cies were resolved by consensus.
The completeness of the search was estimated using
the capture re-capture method [28-30]. Based on this
method, the estimated number of missing articles is 8
(95% CI: 2, 24), which suggests a 90% capture rate (i.e.,
the identified studies cover 90% of the horizon). This
reasonably high capture rate suggests that a sufficient
number of studies were retrieved to avoid bias in the
results of the meta-analysis.
Few of the studies involved comparison groups. Of the
120 studies, 12 were randomized trials (5 comparing
integrated to non-integrated programs) and 25 were
quasi-experimental studies (9 comparing integrated to
non-integrated programs).
This paper focuses on those studies that examined
changes in maternal substance use as such only rando-
mized trials and quasi-experimental studies comparing
integrated programs to non-integrated programs or no
treatment control groups and cohort studies (i.e., pre-
post studies) that reported data on maternal substance
use outcomes were included in the present systematic
327 studies retrieved and 
coded for eligibility 
120120 studies met inclusion 
criteria for larger meta-analysis 
- 44 studies excluded because participants were not women who were pregnant 
or parenting 
- 5 studies excluded because not all participants had a substance use problem at 
baseline 
- 27 studies excluded because the program did not include a substance use 
treatment service addressing substance use specifically 
- 16 studies excluded because the program did not include at least one 
treatment service related to children 
- 6 studies excluded because the participants included men 
- 6 studies excluded because the participants included women who were not 
pregnant or parenting 
- 63 studies were excluded because the study design was not  randomized, 
quasi-experimental, cohort, or cross-sectional (e.g. qualitative, case study) 
- 40 studies were excluded because quantitative results for maternal well-being, 
parenting, or child well-being were not provided 
21 studies met inclusion criteria for 
substance use meta-analysis 
- 96 studies excluded because they did not provide quantitative 
data on substance use outcomes 
- 3 studies excluded because they did not provide sufficient 
data to calculate effect sizes (e.g. standard deviations) 
120 studies met inclusion criteria for 
larger meta-analysis 
Figure 1 Study Eligibility Flowchart.
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randomized trials (n = 250), 9 quasi-experimental stu-
dies (n = 2105), and 10 cohort studies (n = 856).
Coding procedures
We developed a codebook for this systematic review and
meta-analysis based on theoretical models of treatment,
literature review, and data availability. The codebook
was pilot tested by project staff and investigators and
revised during early coding. Variables were added or
deleted, and decisions and clarification of specific vari-
ables were recorded in a coding policy manual.
We coded study context (author, document date, type
of document, country), methodology (sample size, attri-
tion, study design), participant characteristics (age, mari-
tal status, education, employment, income, substance
abuse history, previous substance abuse treatment, men-
tal and physical health, involvement with the legal sys-
tem), child characteristics (age, custody, involvement
with child protection services, positive toxicology at
birth), treatment program characteristics (population
served, planned length of treatment, intensity of treat-
ment, location, services), dependent variable characteris-
tics (type of outcome measure, type of data), and effect
size calculation statistics. There were considerable miss-
ing data (especially on client characteristics and program
services) and limited quantitative data on outcomes (e.g.,
standard deviations, sample sizes). In an attempt to
obtain missing data, we contacted four researchers,
three of whom responded, with two providing additional
data.
Each study was coded by a trained research assistant
(AS), who met frequently with the principal investigator
(KM) during the development of the codebook and
early stage of coding. AS coded all studies and 20% of
studies reporting on maternal substance use outcomes
were coded by both AS and KM. Kappa and percent
agreement were calculated for all variables. There was
100% agreement for identification of dependent vari-
ables. For program and participant variables, there was
94% mean agreement for continuous variables and a
Kappa of. 0.97 for categorical variables. Discrepancies
were resolved by consensus.
Study quality
The Jadad Scale [31,32], widely used in the medical lit-
erature, was used to assess the quality of randomized
trials. On the Jadad Scale, studies are rated on a scale
from 0 to 5, with the highest possible score (5) given for
those with descriptions of: 1) randomization; 2) an
appropriate method of randomization; 3) double-blind-
ing; 4) an appropriate method of double-blinding; and
5) withdrawal and dropouts.
The Newcastle-Ottawa Scale (NOS [33]) was used to
assess the quality of non-randomized studies. On the
NOS, studies are rated on a scale from 0 to 9 on the
basis of three main issues: study group selection; group
comparability; and outcome ascertainment. The content
validity and inter-rater reliability for the NOS have been
established and further evaluation is being conducted
[33].
A trained research assistant (AS) and Master’s student
(JL) coded study quality under the supervision of co-
authors AN and LT. Inter-rater reliability (based on 20%
of the included studies) was high, Kappa = 0.80. Discre-
pancies were resolved by consensus.
Calculating and combining effect sizes
We transformed results from each study to the standar-
dized mean difference (Cohen’s d) using Comprehensive
Meta-analysis II [34]. The standardized mean difference
is computed by subtracting the mean outcome score of
the comparison group from that of the treatment group
and dividing the difference by the pooled standard
deviation. The effect size calculation was based on the
number of participants in the analysis (corrected for
attrition). By convention, an outcome for which the
(integrated) treatment group showed more improvement
than the comparison group was indicated by a positive
sign, whereas an outcome that favored the comparison
group was indicated by a negative sign. Effect sizes were
corrected by inverse variance weights based on standard
error.
When combining effect sizes, we computed both fixed
and random effects to calculate estimates of the impact
of treatment on outcomes across studies [35]. Chi-
square tests of homogeneity were used to assess if
results significantly differed among studies. When signif-
icant heterogeneity was found, random effects findings
rather than fixed effects findings were used [36].
File drawer statistics, which represent the number of
unretrieved studies averaging null results (i.e., not sup-
porting the pattern established by research findings) that
would be required to reduce the significance of the
meta-analytic finding to the just significant level, alpha
= .05 [23], were calculated to assess publication bias.
Moderator analyses
Where there was significant heterogeneity among stu-
dies, we explored factors that may have moderated the
effect of treatment on outcomes using analyses of var-
iance or regression analyses, depending on the type of
moderating variable (categorical or continuous). Poten-
tial moderators included client characteristics (e.g.,
maternal age, education, socioeconomic status, number
of children, age of children, length of stay in treatment),
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program services provided, targeted substance, whether
or not children reside), and study characteristics (e.g.,
design, quality), as have been examined in previous stu-
dies [37,38].
Results
Descriptive information
There was variability across studies in terms of study
design and substance use measures. In terms of study
design, there were 3 randomized trials (n = 250;[39-41]),
9 quasi-experimental studies (n = 2105; [42-50]), and 9
cohort studies (n = 856, [22,51-57] Kerwin, treatment
o u t c o m ed a t af o rw o m e ni ns u b s t a n c ea b u s eg r o u p ,
Unpublished data]). One quasi-experimental study [56]
compared two integrated treatments. Given our research
questions, these groups were examined separately and
included in the cohort data. Substance use measures
included urine toxicology and self report measures, (e.g.,
Addiction Severity Index), percent of participants absti-
nent from substance use, frequency of use, cost of
addiction, negative outcomes of addiction, and change
in use. Given this heterogeneity, we present effect size
information for all studies (see Tables 1, 2 and 3) and
only combine effect sizes for meaningfully similar mea-
sures of maternal substance use.
Study Quality
Study quality scores showed little variability among stu-
dies. Jadad Scale scores for the three randomized trials
were 1, 2, and 3 (absolute range 0-5), which are consid-
ered poor to moderate scores. One study [40] was
described as randomized but did not provide a descrip-
tion of randomization and was not double blind, as par-
ticipants were aware of the treatment allocation. This
study also did not provide a description of withdrawal
and dropouts. The second study [39] was described as
randomized but the method of randomization was not
described. The study was not described as double blind
but did provide a description of withdrawal and drop-
outs. The third study [41] was described as randomized
and an appropriate method of randomization was used.
This study was not described as being double blind but
did provide a description of withdrawal and dropouts.
NOS scores for the quasi-experimental studies varied
from 2 to 6 (maximum possible score = 9), which are
low to moderate scores. The Jadad Scale Score for the
cohort study also was 1. The study [56] was described
as randomized but did not provide a description of the
method of randomization. The study was not described
as being double blind and no description of drop-outs
or withdrawal was provided. Newcastle-Ottawa Scale
Scores for the cohort studies ranged from 0 to 5, which
are low to moderate scores. It was unclear if these low
scores were due to poor study quality or reporting (e.g.,
if there was no description of the ascertainment of treat-
ment exposure, then this item was scored as 0).
Studies of the impact of integrated programs on
maternal substance use
Two studies compared substance use outcomes for
women participating in integrated programs to women
in no treatment control groups. In a quasi-experimental
study, Armstrong et al. [42] examined percent negative
urine screens in 782 integrated program clients and 610
no-treatment control participants and found that
women participating in integrated programs were signif-
icantly more likely than women not in treatment to
have negative urine toxicology screens during pregnancy
(d =0 . 1 8 ,SE =0 . 0 7 ,2.719 p < .01). In a quasi-experi-
mental study of 72 women in integrated programs and
23 women not in treatment, Whiteside-Mansell, Crone,
and Conners [43] examined the percent using drugs and
the percent using alcohol at the time of the birth of
their child. Results indicated that significantly fewer
women in integrated programs used drugs or alcohol
than those not in treatment (d =1 . 4 1( SE = 0.42, z =
3.351, p <. 0 0 1a n dd = 0.49, SE = 0.21, z= 2.287, p =
0.02, for drug and alcohol use, respectively). See Table 1
for further study information.
There were 10 cohort studies with data on maternal
substance use at intake and end of treatment or follow
Table 1 Studies comparing integrated treatment to no treatment
Study n Groups Design Measure d (SE) p Study
Quality
Armstrong & Osejo
43 Treatment:
782
Control:
610
Integrated outpatient treatment vs no
treatment
Quasi-
Experimental
% positive urine
toxicology
0.18
(0.07)
0.007 5/9
Whiteside-Mansell &
Crone
44
Treatment:
72
Control: 23
Integrated Residential treatment vs no
treatment
Quasi-
Experimental
% using alcohol 0.49
(0.22)
0.022 2/5
% using drugs 1.41
(0.42)
0.001
Significance of d based on test of null (z-test).
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Study n Measure d (SE) P Study
Quality
Conners & Bradley
60 62 Number of days of drug use 0.74
† (0.15) 0.001 2/9
62 % using substances 2.90 (0.80) 0.001
Elk & Schmitz
61 19 Addiction Severity Index Alcohol Composite 0.48
‡ (0.24) 0.049 0/9
19 Addiction Severity Index Drug Composite 0.83* (0.27) 0.002
Evenson & Binner
62 98 CSTAR Alcohol and Drug Problem Inventory 0.72 (0.11) 0.001 0/9
98 Cost of Alcohol 0.58 (0.11) 0.001
98 Cost of Drugs 0.74 (0.11) 0.001
98 CSTAR Substance Use Questionnaire - Did not use
substances
2.01 (0.23) 0.001
98 CSTAR Substance Use Questionnaire - Main alcohol/drug
abstinent
1.60 (0.21) 0.001
98 CSTAR Substance Use Questionnaire - Alcohol Abstinent 1.72 (0.26) 0.001
98 CSTAR Substance Use Questionnaire - Alcohol Intox
Abstinent
2.09 (0.35) 0.001
98 CSTAR Substance Use Questionnaire - Cannabis Abstinent 1.88 (0.26) 0.001
98 CSTAR Substance Use Questionnaire - Cocaine Abstinent 2.71 (0.79) 0.001
Ingersoll & Knisely (low psychopathology group)
63
33 Addiction Severity Index Alcohol Composite 0.29
‡ (0.18) 0.102 2/9
33 Addiction Severity Index Drug Composite 0.92* (0.21) 0.000
Ingersoll & Knisely (high psychopathology group)
63
13 Addiction Severity Index Alcohol Composite 0.70 (0.31) 0.023 2/9
13 Addiction Severity Index Drug Composite 0.28* (0.28) 0.322
Kerwin (Treatment outcome data for women
in substance abuse treatment group,
Unpublished data)
7 Addiction Severity Index Alcohol Composite 0.51
‡ (0.32) 0.110 n/a
7 Addiction Severity Index Drug Composite 0.56* (0.32) 0.087
McClellan & Gutman
64 529 Number of days of alcohol use 0.36
† (0.05) 0.001 2
529 Addiction Severity Index Alcohol Composite (6 months
follow up)
0.39 (0.05) 0.001 2
529 Addiction Severity Index Alcohol Composite (12 months
follow up)
0.39
‡ (0.05) 0.001 2
529 Addiction Severity Index Drug Composite (6 month
follow up)
0.63 (0.05) 0.001 2
529 Addiction Severity Index Drug Composite (12 months
follow up)
0.65* (0.05) 0.001 2
529 Money spent on drugs (6 months follow up) 0.21 (0.04) 0.001 2
529 Money spent on drugs (12 months follow up) 0.22 (0.44) 0.001 2
Niccols & Sword
22 9 % using alcohol (3 months into program) 0.31 (0.48) 0.520
7 % using alcohol (6 months into program) 0.31 (0.52) 0.552
9 % using cannabis(3 months into program) 0.99 (0.53) 0.061
7 % using cannabis (6 months into program 0.99 (0.57) 0.083
9 % using cocaine (3 months into program) 1.17 (0.86) 0.175
7 % using cocaine (6 months into program 1.04 (0.87) 0.231
9 % using tranquilizers (3 months into program) 0.73 (0.90) 0.412
7 % using tranquilizers (6 months into program 0.60 (0.90) 0.502
9 % using crack (3 months into program) 0.73 (0.90) 0.412
7 % using crack (6 months into program 0.60 (0.90) 0.502
9 % using barbiturates (3 months into program) 0.73 (0.90) 0.412
7 % using barbiturates (6 months into program 0.60 (0.90) 0.502
9 % using over the counter drugs (3 months into program) 0.00 (0.53) 1.000
7 % using over the counter drugs (6 months into program -0.65 (0.54) 0.239
9 % using other drugs (3 months into program) 0.51 (0.63) 0.419
7 % using other drugs (6 months into program 0.51 (0.69) 0.461
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sures indicated decreased maternal substance use. We
combined studies with the most common measures of
maternal substance use (i.e., Alcohol and Drug Compo-
sites of the Addiction Severity Index and days of use).
Five studies involved the Alcohol and Drug Composites
of the Addiction Severity Index, on which women in
integrated programs reported significantly reducing their
alcohol and drug use from intake to the end of treat-
ment. The overall effect sizes using a fixed effects model
were 0.40 (z= 9.34, p < .001) for the alcohol composite
and 0.65 (z= 14.57, p < .001) for the drug composite
(CIs = - 0.31 to 0.48 and 0.57 to 0.74, respectively). See
Figures 2 and 3. These effect sizes are considered med-
ium (Cohen, 1988). The file drawer statistic indicated
that 66 and 143 studies, respectively, with null results
would be required to reduce significance to the just -
significant level, alpha = 0.05 (Rosenthal, 1991). This
exceeds Rosenthal’s critical value of 35 (5k + 10, where
k is the number of included studies). Therefore, we can
b ec o n f i d e n tt h a tt h e s es i g n i f i c a n tr e s u l t sw o u l dn o tb e
negated by null findings that were not included in the
present analysis. Cochran’s chi square test, which exam-
ines homogeneity of variance, was not statistically signif-
icant for alcohol (Q (4) = 1.58, p = 0.81 and drug (Q (4)
= 3.90, p = 0.42) composites.
Four studies reported on days of use. Results indicated
that women in integrated programs reported signifi-
cantly reducing the number of days using substances
from intake to the end of treatment, z = 3.74, p < .0001.
The overall effect size using a random effects model was
0.52 (CI = 0.25 to 0.80), which is medium [58]. See Fig-
ure 4. The file drawer statistic indicated that 80 studies
with null results would be required to reduce signifi-
cance to just the significant level, alpha =0 . 0 5[ 2 3 ] .
This exceeds Rosenthal’s critical value of 30 (5k + 10,
where k is the number of included studies). Therefore,
we can be confident that this significant result would
not be negated by null findings that were not included
in the present analysis. Given that Cochran’sc h is q u a r e
test indicated significant heterogeneity between studies
(Q (3) = 10.43, p < 0.01), we completed univariate meta-
regression using the following independent variables:
document date, type of document, country, sample size,
attrition, study design, maternal age, marital status, edu-
cation, employment, income, substance abuse history,
previous substance abuse treatment, mental and physical
health, involvement with the legal system, child age, cus-
tody, involvement with child protection services, positive
toxicology at birth, and treatment program characteris-
tics (e.g., program for pregnant and/or parenting
women, planned length of treatment, intensity of treat-
ment, residential or outpatient, type of services). These
variables did not significantly moderate the substance
use effect. It is important to note that, due to missing
data and our inability to include all studies in all ana-
lyses, these analyses may have been underpowered.
Studies comparing integrated programs to non-
integrated programs
There were 10 studies comparing substance use for
women participating in integrated and non-integrated
programs. As can be seen in Table 3, 9 out of 16 mea-
sures indicated better outcomes for integrated programs
and most of these effect sizes were small and non-signif-
icant. We combined studies with the most common
measures of maternal substance use (urine toxicology
and self-report abstinence, i.e., percent not using). Four
studies examining urine toxicology indicated no signifi-
cant differences between integrated and non-integrated
programs. Carroll et al. [39] found that 71% of inte-
grated and 76% of non-integrated program clients had
negative urine screens (n = 7 in each group). Similarly,
Barkauskas, Low, & Pimlott [44] found that 95% of inte-
grated and 97% of non-integrated program clients had
negative urine screens (n = 37 and 35, respectively).
Chang, Carroll, Behr, & Kosten [45] examined 6 inte-
grated and 6 non-integrated program clients and found
that more integrated program clients had negative urine
screens (41% and 24%, respectively). Luthar et al. [41]
compared a relational psychotherapy mothers group
plus standard methadone treatment (treatment group)
Table 2: Cohort studies examining changes in maternal substance use (Continued)
Volpicelli & Markman
42 21 Number of days of cocaine use 0.753
†
(0.247)
0.002 1/9
21 Number of days of cocaine use 0.423
†
(0.228)
0.063 1/9
Wexler & Cuadrado
65 44 % using alcohol 0.37 (0.28) 0.191
44 % using drugs 3.06 (0.81) 0.001
†Study included in the overall effect size for number of days of substance use
‡Study included in the overall effect size for Addiction Severity Index Alcohol Composite
*Study included in the overall effect size for Addiction Severity Index Drug Composite
◊ Comprehensive Substance Abuse Treatment and Rehabilitation
Significance of d based on test of null (z-test).
Milligan et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:21
http://www.substanceabusepolicy.com/content/5/1/21
Page 8 of 14with a recovery training plus standard methadone treat-
ment (control group) on opiate and cocaine screens (n
= 60 and 67, respectively). No significant group differ-
ences were found on opiate or cocaine screens. Taken
together, the combined effect size data for these 4 stu-
dies suggest that the percentage of clients with negative
urine screens in integrated and non-integrated programs
was not significantly different (d = -0.09, CI = -0.412 to
0.224, z= -0.58, p = 0.56). Cochran’s chi square test indi-
cated that there was no statistically significant heteroge-
neity among studies, Q (3) = 0.66, p = 0.88.
There were two studies comparing self-reported absti-
nence for women in integrated and non-integrated pro-
g r a m s .S o w e r s ,E l l i s ,W a s h i n g t o n ,&C u r r a n t[ 4 8 ]
Table 3 Studies comparing integrated to non-integrated treatment
Study n Groups Design Measure d (SE) p Study
Quality
Barkauskas
and Low
46
Treatment:
52
Control: 73
Residential program for pregnant, incarcerated
women vs standard prison care for women
Quasi-
Experimental
% positive toxicology screens -0.29
†
(0.69)
0.669 5/9
Carroll and
Chang
40
Treatment:
7
Control: 7
Enhanced methadone treatment for women
vs standard methadone treatment for women
Randomized
Trial
% positive toxicology screens -0.14
†
(0.67)
0.83 1/5
Chang and
Carroll
47
Treatment:
6
Control: 6
Enhanced methadone treatment for women
vs standard methadone treatment for women
Quasi-
experimental
% positive toxicology screens 0.43
†
(0.70)
0.54 3/9
Gwadz and
Leonard
39
Treatment:
51
Control: 58
Integrated outpatient treatment for women vs
standard outpatient treatment for women
Randomized
Trial
National Alcohol Survey -
Frequency of Alcohol Use
-0.12
(0.19)
0.545 1/5
Drug Use Screen Inventory -
Alcohol/Dru g Problems
0.077
(0.19)
0.69
Risk Behaviour Assessment -
Frequency of Drug Use
-0.26
(0.19)
0.183
Harshman
66 Treatment:
25 Control:
27
Residential Integrated treatment for women vs
Co-ed Residential Standard treatment
Quasi-
experimental
# months since last used
substances
-0.15
(0.28)
0.593 2/9
SASSI-2 * Alcohol use 0.61
(0.28)
.033
SASSI-2 drug use 0.06
(0.28)
0.83
Luthar et
al.
41
Treatment:
60 Control:
67
Maternal psychotherapy plus standard
methadone treatment vs. Recovery training
plus standard methadone treatment
Randomized
Trial
Positive toxicology screens -
opiate use (follow up phase - up
to one year follow up)
-0.08
†
(0.18)
0.647 3/9
Positive toxicology screens -
cocaine use (treatment phase)
0.25
(0.18)
0.170
Positive toxicology screens -
cocaine use (follow up phase -
up to one year follow up)
-0.14
†
(0.18)
0.428
Sacks and
Sacks
67
Treatment:
49
Control: 49
Residential integrated treatment for women vs
co-ed standard residential treatment
Quasi-
experimental
Substance Use Composite (incl.
Drug use, frequency of use, #
days of use)
0.12◊ NS 3/9
Sowers and
Ellis
48
Treatment:
26
Control: 15
Residential integrated treatment for women vs
standard day treatment (not specified if
women only)
Quasi-
experimental
% not using any substances 0.33
(0.36)
0.36 4/9
Suchman
and Mayes
49
treatment:
25
control: 23
Women only outpatient treatment with
parenting intervention vs standard women
only outpatient treatment
Quasi-
Experimental
% not using any substances 0.15
(0.30)
0.628 3/9
Touissaint
and
VanDeMar
k
68
Treatment:
64
Control:
106
Residential Integrated Treatment for women
vs Co-ed Residential Standard Treatment
Quasi-
experimental
Addiction Severity Index Drug
Composite
0.30
(0.16)
.059 6/9
Addiction Severity Index Alcohol
Composite
0.28
(0.16)
0.078 6/9
† Included in overall effect size for toxicology screens
* Substance Abuse Subtle Screening Inventory-2
◊ effect size reported, data on SE and p not available
Significance of d based on test of null (z-test)
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Page 9 of 14examined differences in abstinence for integrated resi-
dential treatment and non-integrated day treatment. A
moderate effect was found (d = 0.33) but was not statis-
tically significant. Suchman, Mayes, Conti, Slade, &
Rounsaville [49] found a small, non-significant effect (d
= 0.15) when comparing abstinence for women in
women-only outpatient treatment programs with or
without parenting services. Taken together, the
combined effect size data suggest that the percentage of
clients reporting abstinence in integrated and non-inte-
grated programs was not significantly different (d =
0.22, CI = -0.231 to 0.672, z= 0.96, p = 0.34). There was
no statistically significant heterogeneity among studies,
Q (1) = 0.158, p = 0.691.
Discussion
This systematic review and meta-analysis addressed the
effectiveness of integrated programs for women with
substance use issues and their children in improving
maternal substance use outcomes. In the two studies of
w o m e ni ni n t e g r a t e dp r o g r ams versus no treatment,
effect sizes for substance use (urine toxicology and per-
cent using drugs or alcohol) significantly favored inte-
grated programs and ranged from 0.18 to 1.41, which
are small to large in strength. In the five cohort studies
involving measures of severity of drug and alcohol use
for women in integrated programs, the average effect
sizes were 0.64 and 0.40, respectively. In the four cohort
studies of number of days of substance use for women
in integrated programs, the average effect size was 0.52.
These cohort study effects were statistically significant,
medium size, and indicated that integrated programs are
effective in reducing the severity of substance use and
the number of days of substance use from beginning to
end of treatment. These findings are consistent with
research that has shown that substance use treatment
programs are generally effective in reducing substance
use [59-61].
In our meta-analysis of studies comparing women who
participated in integrated programs to women who par-
ticipated in non-integrated programs, there were four
studies assessing urine toxicology and two studies asses-
sing self-reported abstinence. Overall effect sizes were
-0.09 and 0.22 and both were nonsignificant. These
results are similar to Orwin et al.’s [18] meta-analysis of
studies comparing women-only programs to mixed gen-
der programs, in which substance use effects favoring
women-only programs were small and non-significant.
The lack of significant differences between integrated
and non-integrated programs may, in part, reflect meth-
odological limitations, including issues relating to mea-
surement of substance use.
Operationalization of substance use
The most common measures of substance use in treat-
ment studies are abstinence measures (e.g., urine toxi-
cology, percent using) or frequency of use (e.g., number
of days of use). While these measures provide
-1.00 -0.50 0.00 0.50 1.00
Figure 2 Forest Plot for ASI Alcohol Composite.
-1.00 -0.50 0.00 0.50 1.00
Figure 3 Forest Plot for ASI Drug Composite.
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Page 10 of 14information about substance use, they do not reflect the
complexity of substance use and may not fully reflect
changes made by women in treatment. For example, fre-
quency measures do not account for changes in quantity
(e.g., the number or strength of drinks or level of intoxi-
cation) or type of substance used. Similarly, urine toxi-
cology measures are useful for measuring abstinence as
reflected by recent substance use (past 2-3 days), but
cannot provide information about reduction in use or
changes in the pattern of use over a longer time period
[38]. Reduced use would have particular significance, for
example, if it was associated with reduced impairment
or reduced use of illegal substances [48]. Therefore, sub-
stance use is best represented as a pattern of behavior
reflecting variables such as quantity, frequency, duration
of use, impact, and type of substance [62]. In our meta-
analysis, studies involving a multi-dimensional measure
of substance use (the Addiction Severity Index) had sig-
nificant, medium-sized effects whereas studies involving
unidimensional measures of abstinence (urine toxicol-
ogy) had small, nonsignificant effects. Therefore, the
manner in which substance use is operationalized and
measured may impact on the size of observed effects.
Theoretical specificity of outcome measures
The extent to which substance use measures are theore-
tically specified to the treatment model also may impact
effects. For example, programs using a harm-reduction
approach to treatment that only use measures of absti-
nence to assess change may potentially miss clinically
significant improvements in substance use. Urine toxi-
cology is the most commonly used biological assay
method for illicit drugs. Urine toxicology allows one to
assess what percentage of participants have not been
using drugs in the immediate past. However, at least
some of “abstinent” participants may have used drugs
over the total assessment period [38]. Abstinence-based
measures also cannot account for reduced substance use
or changes in substances used. Therefore, it is possible
that abstinence measures may over- or underestimate
substance use. The National Institute on Alcohol Abuse
and Alcoholism, Project MATCH Research Group [63]
found that while participants decreased their alcohol
consumption, most continued to use alcohol at a
decreased level at one year follow up. Despite the advan-
tages of urine toxicology as an objective measure of
abstinence, substance use treatment studies, particularly
those adopting a harm reduction treatment model,
should include multi-dimensional measures of substance
use to fully capture the changes made by women.
Reliability of self-report measures
Self-report measures are commonly used in the field.
The reliability of self-report measures of substance use
over a specific time period since leaving treatment (for
example, the past 6 months) is open to question. While
underreporting is common [64,65], there is some evi-
dence that treatment participants may be more likely to
report that they have used drugs than those who have
not been in treatment [38,66]. These reporting biases
may obscure differences between groups and impact
observed effects. It is also possible that self-report mea-
sures of substance use may be less reliable and valid
than self-reports of other outcomes [67,68]. In part, this
may explain why Orwin et al. [18] found larger effects
for maternal and child well-being outcomes than sub-
stance use in their meta-analysis comparing women-
only to mixed gender treatment programs.
Limitations
There were a number of challenges encountered in con-
ducting this meta-analysis, including few comparison
group studies, low levels of study quality, and a high
level of missing data.
-1.00 -0.50 0.00 0.50 1.00
Figure 4 Forest Plot for Days of Use.
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The majority of studies included in the meta-analysis
involved a cohort research design, with relatively few
studies examining differences between integrated and
non-integrated programs. While we were able to include
data comparing 3111 women in our review, the size of
the observed effects may have been impacted by the
small number of studies. As with the substance abuse
treatment field generally, most program evaluations
involved non-random designs and tested correlational
rather than causal relations [38]. Finally, the small num-
ber of studies made it difficult to explore moderators of
treatment effect and to determine what treatment is
best for whom under what circumstances.
Study quality
Studies included in the meta-analyses were assessed as
being of low to moderate quality, although it was
unclear if the scores reflected study quality per se or the
reporting of study quality elements. It is possible that
the study quality ratings, particularly for the randomized
trials, may have been underestimated. The Jadad scale
used to assess the quality of randomized trials is a very
conservative measure of study quality that addresses
methodological characteristics such as studies being
double blind. Such characteristics may be impractical to
implement in substance abuse treatment research.
Despite this limitation, there are areas of study quality
that can be improved. For example, only 48% of studies
included information about attrition. The manner in
which attrition is addressed statistically (e.g., omitting
these participants, intent to treat method) has the
potential to limit the validity of results [69]. An empha-
sis on high quality randomized or quasi-experimental
designs comparing clearly defined integrated and non-
integrated treatments is needed to move the field
forward.
Missing study information
It was surprising how often essential information about
a study or program was unavailable. Missing study
information needed to calculate effect sizes led to some
studies not being included in the present meta-analysis.
It also impeded our exploration of participant and pro-
gram characteristics that might moderate substance use
outcomes. Ensuring the availability of essential informa-
tion to describe studies for future meta-analyses on inte-
grated programs could be accomplished by
improvements in the editorial review process and crea-
tion of a registry of funded studies that would require
submission of standard information (such as the
Cochrane Collaboration on health care intervention)
[38].
Conclusion
The findings from this meta-analysis suggest that inte-
grated programs for women with substance use issues
and their children are associated with significant reduc-
tion in substance use.
However, integrated programs were not associated
with significantly more reduction in substance use com-
pared to non-integrated programs. While these findings
suggest that the current evidence base does not support
integrated over non-integrated programs for reduction
of substance use, there are a number of important lim-
itations raised by this meta-analysis and synthesis that
merit attention from a policy perspective. Given the few
comparison group studies and low levels of study quality
seen in the current review, scarce research funding
resources need to be directed towards high quality pro-
spective studies with randomized designs and larger
samples. The field will advance only as researchers con-
duct high quality studies that manipulate treatment con-
ditions, rather than examini n gt h e mp o s th o c ,a n dt h a t
take into account the diversity of substance-using popu-
lations. Reporting practices also need to be improved
and standardized to include full descriptions of the tar-
get population and the intervention program.
To our knowledge, this meta-analysis is the first sys-
tematic quantitative review of studies evaluating the spe-
cific impact of integrated treatment programs on
maternal substance use. Given that approximately one
third of people with drug dependence are women of
child-bearing age [10], substance use during pregnancy
is a major public health concern [1] and burden of suf-
fering due to maternal substance abuse is great, the
findings from this study are noteworthy and support
funding for further research on integrated programs for
women with substance abuse issues and their children.
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